MAGICAL DRUG: Michael Evans doesn’t use the C-word.
He doesn’t want to jinx his luck. Technically, the 37-year-old still has multiple sclerosis. But after being symptom-free for almost two years, the “miracle drug” Evans received in a clinical trial is close to a c-u-r-e as he can imagine.
"This is how I felt before I was even diagnosed," Evans said. "Alemtuzumab isn’t just telling my immune system to knock things off, it’s making things better."
On Wednesday, participants in the clinical trial will testify before a U.S. Food and Drug Administration advisory committee about how Alemtuzumad has changed their lives. While a work conflict is preventing Evans from testifying, he still wants people to know about the groundbreaking medicine.
(Photo credit: Dan Powers/Post-Crescent Media)

MAGICAL DRUG: Michael Evans doesn’t use the C-word.

He doesn’t want to jinx his luck. Technically, the 37-year-old still has multiple sclerosis. But after being symptom-free for almost two years, the “miracle drug” Evans received in a clinical trial is close to a c-u-r-e as he can imagine.

"This is how I felt before I was even diagnosed," Evans said. "Alemtuzumab isn’t just telling my immune system to knock things off, it’s making things better."

On Wednesday, participants in the clinical trial will testify before a U.S. Food and Drug Administration advisory committee about how Alemtuzumad has changed their lives. While a work conflict is preventing Evans from testifying, he still wants people to know about the groundbreaking medicine.

(Photo credit: Dan Powers/Post-Crescent Media)